Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Presentation Details
| Could Elevated Homocysteine Be a Risk Factor for Cerebral Venous Thrombosis? Nawris Alhassan1, Jagdish Lal2, Susmin Karki3. 1Hope Clinic, Midvale, UT, USA.2Burnaby Chronic Pain & Rehabilitation Clinic, Burnaby, BC, Canada.3Institute of Medicine, Tribhuvan University, Maharajgunj, Nepal |
Abstract
Background: Cerebral venous thrombosis is relatively rare, but has severe thrombotic manifestations with a high mortality rate, the potential to cause disability, and the propensity to recur. There is limited data on the role of hyperhomocysteinemia as a risk factor for CVT. In this context, no large-scale meta-analysis has been conducted. Our meta-analysis aims to assess hyperhomocysteinemia as a risk factor for cerebral venous thrombosis (CVT) using the data from case-control studies. Methods: We conducted a meta-analysis to look for hyperhomocysteinemia as a risk factor among CVT patients. A literature search was conducted using PubMed, Embase, and Google Scholar databases until August 2025. A meta-analysis was performed using high-quality case-control studies comparing the homocysteine level in patients with CVT cases and healthy controls. At least two authors extracted summary data. Between studies, heterogeneity was assessed using the I² statistic. For each exposure-outcome pair, a random or fixed effect meta-analysis was conducted based on the degree of heterogeneity to pool the odds ratio (OR), prevalence of hyperhomocysteinemia, and the mean difference (MD) in homocysteine level with a 95% confidence interval (CI) from the individual studies using Revman version 5.4. Results: This meta-analysis included 6 eligible studies. These studies involved 1355 participants (455 CVT cases, 900 controls). There were 123 males in the CVT group and 295 males in the control group. There was a statistically significantly increased risk of CVT among the patients with hyperhomocysteine levels [OR =4.17, CI = 2.34 to 7.43, P value <0.00001, I2 = 70%]. Furthermore, the homocysteine level was significantly higher in the CVT patients as compared with the healthy controls (MD= 7.00, 95% CI =3.21 to 10.79, I2=88%, P value= 0.0003). The prevalence of hyperhomocysteine levels among CVT patients was higher compared with the healthy controls (37%, 95% CI =29% to 46%, I2=66%) versus (15%, 95% CI= 9% to 23%, I2=90.4%). Conclusions: In conclusion, there is a strong association between CVT and hyperhomocysteinemia, as per this meta-analysis. Furthermore, the prevalence of hyperhomocysteinemia was found to be significantly high among CVT patients. Hence, hyperhomocysteinemia should be considered a potential risk factor in patients presenting with CVT. Since limited studies and subjects were included, larger-scale association studies are necessary to validate the risk of CVT among hyperhomocysteinemia. Keywords: Cerebral venous thrombosis, hyperhomocysteinemia, meta-analysis, systematic review, risk factor
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.